Teva Pharmaceutical (TEVA) Receives a Hold from J.P. Morgan
In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
FiercePharma28d
Teva looks to peel back the onion on mental health: exec
The drug was first approved in the 1990s and is currently marketed by Eli Lilly under the brand name Zyprexa. Teva, which launched a Dr. Reddy’s-partnered generic to Zyprexa in 2011, spotted a ...
STAT12d
Pharmalittle: We’re reading about lower-priced Zepbound vials, monkey shipments from Cambodia, and more
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
Hosted on MSN12d
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...
Investing4d
Eli Lilly and Co BDR (LILY34)
This page features the latest news about the Eli Lilly and Co BDR stock. Eli Lilly ordered to pay $176.5 million to Teva in U.S. migraine drug patent trial By Blake Brittain (Reuters ...